Efficacy of NEPA, a fixed antiemetic combination of netupitant and palonosetron, vs a 3‐day aprepitant regimen for prevention of chemotherapy‐induced nausea and vomiting (CINV) in Chinese patients receiving highly emetogenic chemotherapy (HEC) in a randomized Phase 3 study

NEPA is the only fixed combination antiemetic, comprised of an NK(1)RA (netupitant) and a 5‐HT(3)RA (palonosetron). In the first head‐to‐head trial to compare NK(1)RA‐containing regimens, a single oral dose of NEPA was non‐inferior to a 3‐day aprepitant/granisetron (APR/GRAN) regimen for the primary...

Descripción completa

Detalles Bibliográficos
Autores principales: Chang, Jianhua, Chen, Gongyan, Wang, Dong, Wang, Guihua, Lu, Shun, Feng, Jifeng, Li, Wei, Li, Ping, Lanzarotti, Corinna, Chessari, Salvatore, Zhang, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7367622/
https://www.ncbi.nlm.nih.gov/pubmed/32472742
http://dx.doi.org/10.1002/cam4.3123

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7367622/
https://www.ncbi.nlm.nih.gov/pubmed/32472742
http://dx.doi.org/10.1002/cam4.3123

Ejemplares similares